These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 32873605)
1. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity. Kotanides H; Li Y; Malabunga M; Carpenito C; Eastman SW; Shen Y; Wang G; Inigo I; Surguladze D; Pennello AL; Persaud K; Hindi S; Topper M; Chen X; Zhang Y; Bulaon DK; Bailey T; Lao Y; Han B; Torgerson S; Chin D; Sonyi A; Haidar JN; Novosiadly RD; Moxham CM; Plowman GD; Ludwig DL; Kalos M Cancer Immunol Res; 2020 Oct; 8(10):1300-1310. PubMed ID: 32873605 [TBL] [Abstract][Full Text] [Related]
2. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity. Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527 [TBL] [Abstract][Full Text] [Related]
3. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. Osada T; Patel SP; Hammond SA; Osada K; Morse MA; Lyerly HK Cancer Immunol Immunother; 2015 Jun; 64(6):677-88. PubMed ID: 25742933 [TBL] [Abstract][Full Text] [Related]
4. FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity. Kraman M; Faroudi M; Allen NL; Kmiecik K; Gliddon D; Seal C; Koers A; Wydro MM; Batey S; Winnewisser J; Young L; Tuna M; Doody J; Morrow M; Brewis N Clin Cancer Res; 2020 Jul; 26(13):3333-3344. PubMed ID: 32299814 [TBL] [Abstract][Full Text] [Related]
5. Engineered mRNA-expressed bispecific antibody prevent intestinal cancer via lipid nanoparticle delivery. Wu L; Wang W; Tian J; Qi C; Cai Z; Yan W; Xuan S; Shang A Bioengineered; 2021 Dec; 12(2):12383-12393. PubMed ID: 34895063 [TBL] [Abstract][Full Text] [Related]
6. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer. Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201 [TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968 [TBL] [Abstract][Full Text] [Related]
8. PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity. Jiang H; Ni H; Zhang P; Guo X; Wu M; Shen H; Wang J; Wu W; Wu Z; Ding J; Tang R; Zhou S; Chen B; Yu M; Jing H; Liu J Oncoimmunology; 2021; 10(1):1943180. PubMed ID: 34239776 [TBL] [Abstract][Full Text] [Related]
9. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy. Vitale LA; He LZ; Thomas LJ; Wasiuk A; O'Neill T; Widger J; Crocker A; Mills-Chen L; Forsberg E; Weidlick J; Patterson C; Hammond RA; Boyer J; Sisson C; Alvarado D; Goldstein J; Marsh HC; Keler T Cancer Immunol Immunother; 2020 Oct; 69(10):2125-2137. PubMed ID: 32451681 [TBL] [Abstract][Full Text] [Related]
10. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy. Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181 [TBL] [Abstract][Full Text] [Related]
11. Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells. Pandey MS; Wang C; Umlauf S; Lin S Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768776 [TBL] [Abstract][Full Text] [Related]
12. A Novel Bispecific Antibody with PD-L1-assisted OX40 Activation for Cancer Treatment. Kuang Z; Pu P; Wu M; Wu Z; Wang L; Li Y; Zhang S; Jing H; Wu W; Chen B; Liu J Mol Cancer Ther; 2020 Dec; 19(12):2564-2574. PubMed ID: 32999045 [TBL] [Abstract][Full Text] [Related]
13. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. Lin S; Huang G; Cheng L; Li Z; Xiao Y; Deng Q; Jiang Y; Li B; Lin S; Wang S; Wu Q; Yao H; Cao S; Li Y; Liu P; Wei W; Pei D; Yao Y; Wen Z; Zhang X; Wu Y; Zhang Z; Cui S; Sun X; Qian X; Li P MAbs; 2018; 10(8):1301-1311. PubMed ID: 30204048 [TBL] [Abstract][Full Text] [Related]
14. LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation. Sung E; Ko M; Won JY; Jo Y; Park E; Kim H; Choi E; Jung UJ; Jeon J; Kim Y; Ahn H; Choi DS; Choi S; Hong Y; Park H; Lee H; Son YG; Park K; Won J; Oh SJ; Lee S; Kim KP; Yoo C; Song HK; Jin HS; Jung J; Park Y Mol Ther; 2022 Aug; 30(8):2800-2816. PubMed ID: 35526096 [TBL] [Abstract][Full Text] [Related]
16. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity. Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020 [TBL] [Abstract][Full Text] [Related]
17. ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation. Yuwen H; Wang H; Li T; Ren Y; Zhang YK; Chen P; Sun A; Bian G; Li B; Flowers D; Presler M; Subramanian K; Xue J; Wang J; Lynch K; Mei J; He X; Shan B; Hou B Cancer Res; 2024 May; 84(10):1680-1698. PubMed ID: 38501978 [TBL] [Abstract][Full Text] [Related]
18. The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 × αPD-L1 bispecific antibody-armed T cells. Cho J; Tae N; Song Y; Kim CW; Lee SJ; Ahn JH; Lee KH; Lee BH; Kim BS; Chang SY; Kim DH; Ko HJ Cancer Immunol Immunother; 2024 Aug; 73(10):196. PubMed ID: 39105814 [TBL] [Abstract][Full Text] [Related]
19. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401 [TBL] [Abstract][Full Text] [Related]